莎普爱思：硫酸特布他林雾化吸入用溶液获药品注册证书

Core Viewpoint - The company received a drug registration certificate from the National Medical Products Administration for a new medication, which is expected to alleviate respiratory conditions such as bronchial asthma and chronic bronchitis [1] Company Summary - The newly approved medication is a sulfate terbutaline aerosol inhalation solution [1] - This drug is indicated for the relief of bronchospasm associated with bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases [1]